The biological effects of immunosuppression on cellular immunotherapy
- 29 February 1992
- journal article
- research article
- Published by Elsevier BV in Surgical Oncology
- Vol. 1 (1), 27-35
- https://doi.org/10.1016/0960-7404(92)90053-n
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCERThe Lancet, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.The Journal of Experimental Medicine, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Down-Regulation of the Antitumor Immune ResponseAdvances in Cancer Research, 1985
- Cyclophosphamide (Cytoxan): A review on relevant pharmacology and clinical usesJournal of the American Academy of Dermatology, 1984
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958